At Eradigm we work to optimize pricing and access strategy by dovetailing these with short, medium and long term product goals and strategies, contextualised within market-specific evidence requirements, payer goals, and competitive threats.
Our deep expertise in pricing, access paired with a strategy consultant approach, and evidence planning, allow us to help our clients navigate complex global P&MA environments. Our deep market-specific insights help shape and refine P&MA strategies, linking them to broader commercial goals. This mix of P&MA and broader commercial expertise allows us to serve our clients’ market access, clinical, and commercial experts.
We work across all key major and emerging markets, providing bespoke strategic support in launch price setting and adjustments, launch sequencing, competitive entry strategy, contracting strategy, and evidence generation strategies.
Market Access Strategy
- US and Global P&MA landscape assessment
- Global launch strategy, sequencing, and prioritisation
- Disruptive trend analysis
- Framework development
- Indication sequencing
- Portfolio P&MA strategy
Pricing and Reimbursement
- Early pricing strategy
- Launch pricing
- Life cycle management pricing
- Innovative pricing and contracting strategy
- Contract modelling
- Gross-to-net forecasting
Diligence support
- P&MA due diligence
- Assumption pressure testing
Value and evidence
- Integrated HTA & payer evidence planning
- Payer and value proposition development
- Value driver analysis
- Out of pocket pricing strategies
- Market Access Capability Building
- Mock negotiation workshops
- HEOR